---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-281969"
form_type: "8-K"
ticker: "JAGX"
cik: "0001585608"
company_name: "Jaguar Health, Inc."
filed_at: "2026-06-25T13:15:57+00:00"
generated_at: "2026-06-25T13:17:28.605430+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Jaguar Health converts Series O Preferred Stock to common at 3.209:1, pays $2.68 for fractions

## Summary
- Each share of Series O Preferred Stock converted into 3.209 common shares on June 25, 2026; fractional shares paid in cash at $2.68/share.
- Preferred stock was issued as a one-time stock dividend to common stockholders and warrant holders of record March 2, 2026.
- Company targeting Breakthrough Therapy designation for crofelemer in MVID with NDA filing planned for H1 2027.
- Initial MVID patient in proof-of-concept trial showed up to 37% reduction in parenteral support needs; data presented at ESPGHAN June 2026.
- First Amendment to supply agreement with Woodward clarifies inventory title transfer and transition period through Dec 31, 2026.

## SEC filing metadata
- accession: 0001193125-26-281969
- form_type: 8-K
- ticker: JAGX
- cik: 0001585608
- company_name: Jaguar Health, Inc.
- filed_at: 2026-06-25T13:15:57+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585608/000119312526281969/0001193125-26-281969-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585608/000119312526281969/d110630d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-281969
- JSON: https://secwatch.observer/filing/0001193125-26-281969.json
- Plain text: https://secwatch.observer/filing/0001193125-26-281969.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.